Digest Network Come funziona
Network
/
Società
Ka
Non verificato

Kairos Pharma, Ltd

Di cosa scriviamo

BiotecnologiaFarmaceuticaOncologiaSaluteScienza

26 comunicati stampa

Guarda tutti i comunicati
02/03/2026
Mercato del lavoro
Software
Biotecnologia
Farmaceutica
Oncologia
Salute
Tecnica
Medicina - Varie
Kairos Pharma Announces Signing of Binding Strategic Asset Acquisition of Exclusive Worldwide Rights to CL-273 From OrbiMed and Torrey Pines Investment-Backed Celyn Therapeutics
Fonte
Kairos Pharma, Ltd
Emittente
Business Wire
1.00
0
26/02/2026
Mercato azionario
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets from Celyn Therapeutics
Fonte
Kairos Pharma, Ltd
Emittente
Business Wire
1.00
0
20/01/2026
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Eventi
Kairos Pharma to Present at 3rd Annual DealFlow Discovery Conference
Fonte
Kairos Pharma, Ltd
Emittente
Business Wire
1.00
0
17/12/2025
Eventi
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Kairos Pharma Wins 2025 Clinical Trials Arena Research and Development Excellence Award for Advanced Prostate Cancer
Fonte
Kairos Pharma, Ltd
Emittente
Business Wire
1.00
0
20/10/2025
Oncologia
Salute
Scienza
Farmaceutica
Biotecnologia
Eventi
Industria
Kairos Pharma Presents on Phase 2 Trial of ENV-105 in Advanced Prostate Cancer at European Society Medical Oncologists (ESMO) Meeting
Fonte
Kairos Pharma, Ltd
Emittente
Business Wire
1.00
0
07/10/2025
Salute
Scienza
Farmaceutica
Oncologia
Eventi
Kairos Pharma to Present Positive Safety and Efficacy Data from Phase 2 Prostate Cancer Trial at ESMO 2025
Fonte
Kairos Pharma, Ltd
Emittente
Business Wire
1.00
0
18/09/2025
Farmaceutica
Salute
Oncologia
Medicina - Varie
Web e Social Network
Industria
Kairos Pharma Announces Positive Interim Efficacy Analysis of Phase 2 Trial of ENV105 in Advanced Prostate Cancer with Median Progression Free Survival of Over One Year
Fonte
Kairos Pharma, Ltd
Emittente
Business Wire
1.00
0
11/09/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Eventi
Finanza
Web e Social Network
Kairos Pharma Announces Virtual KOL Event to Provide Perspectives on ENV105 Interim Efficacy Results in Advanced Prostate Cancer
Fonte
Kairos Pharma, Ltd
Emittente
Business Wire
1.00
0
03/09/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Eventi
Fiere
Industria
Kairos Pharma Announces Presentation of New Phase 1 Data on ENV105 Combination Therapy in Non-Small Cell Lung Cancer at the World Lung Cancer Conference September 6-9, 2025
Fonte
Kairos Pharma, Ltd
Emittente
Business Wire
1.00
0
02/09/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Web e Social Network
Eventi
Finanza
Kairos Pharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Fonte
Kairos Pharma, Ltd
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0